Company intelligence / Profile preview

Neuros Medical

Willoughby Hills, Ohio, USAneurosmedical.com ↗

Ownership: Private
Employees: ~7
Development stage: Commercial

Overview

The Altius system is FDA-approved for the treatment of chronic post-amputation pain. In a 12-month clinical study, patients experienced an average 30% reduction in pain within 30 minutes of starting a session and about 50% reduction after 120 minutes. Additionally, there was an 81% decrease or elimination in opioid use among patients, with a reported improvement in quality of life by 45%. The QUEST pivotal trial demonstrated safety and effectiveness for this indication.

Therapeutic areas: Neurology
Modalities: DeviceNeuromodulation device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Altius

Commercial

Indications: Chronic post-amputation pain, Phantom limb pain, Residual limb pain

Partnerships

Veterans Healthcare Supply Solutions (to provide treatment at VA Healthcare and Military Treatment Facilities)

Beyond the preview

Go deeper on Neuros Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuros Medical.

Explore the full profile